Pegaspargase
- Generic Name
- Pegaspargase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 130167-69-0
- Unique Ingredient Identifier
- 7D96IR0PPM
- Background
Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synt...
- Indication
Pegaspargase is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of pediatric and adult patients with 1) first-line acute lymphoblastic leukemia or 2) acute lymphoblastic leukemia and hypersensitivity to asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
- Conditions
- Interventions
- Drug: ChidamideDrug: DexamethasoneDrug: vincristineDrug: CyclophosphamideDrug: IdarubicinDrug: PegaspargaseDrug: AdriamycinDrug: MethotrexateDrug: 6-MercaptopurineDrug: EtoposideDrug: CytarabineProcedure: Bone marrow aspirationProcedure: Intrathecal injectionRadiation: Radiation therapyGenetic: NGSProcedure: allogeneic hematopoietic stem cell transplantationDiagnostic Test: Flow-MRDDiagnostic Test: FISHDiagnostic Test: Flow immunophenotypingDiagnostic Test: Karyotyping
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 70
- Registration Number
- NCT03553238
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Julio Barredo, MD
- Target Recruit Count
- 6
- Registration Number
- NCT03349281
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT03318419
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: PrednisoneDrug: VincristineDrug: DaunorubicinDrug: PegaspargaseDrug: Erwinase®Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: DasatinibDrug: MethotrexateDrug: BlinatumomabDrug: DexamethasoneDrug: RuxolitinibDrug: ThioguanineDrug: BortezomibDrug: Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug: Calaspargase PegolDrug: DoxorubicinDrug: EtoposideDrug: NelarabineDrug: ClofarabineDrug: VorinostatDrug: Idarubicin
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 560
- Registration Number
- NCT03020030
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇨🇦Hospital Sainte Justine, University of Montreal, Montreal, Quebec, Canada
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Calaspargase PegolProcedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Dexrazoxane HydrochlorideDrug: DoxorubicinDrug: EtoposideBiological: FilgrastimDrug: IfosfamideDrug: Imatinib MesylateDrug: MethotrexateOther: Laboratory Biomarker AnalysisDrug: Leucovorin CalciumDrug: PegaspargaseDrug: PrednisoloneDrug: MercaptopurineDrug: MethylprednisoloneOther: Questionnaire AdministrationDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 475
- Registration Number
- NCT03007147
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Asparaginase Erwinia chrysanthemiProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyDrug: Calaspargase PegolDrug: CyclophosphamideDrug: CytarabineProcedure: Diagnostic ImagingBiological: Inotuzumab OzogamicinDrug: Leucovorin CalciumProcedure: Lumbar PunctureDrug: MethotrexateDrug: PegaspargaseDrug: Vincristine
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 80
- Registration Number
- NCT02981628
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸Banner Children's at Desert, Mesa, Arizona, United States
PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2020-01-28
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02918747
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
L-DEP as an Initial Treatment for EBV-HLH
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02912702
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: ClofarabineDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DasatinibDrug: DexamethasoneOther: Laboratory Biomarker AnalysisDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Hydrocortisone Sodium SuccinateDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: PrednisoneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2016-08-30
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5949
- Registration Number
- NCT02883049
- Locations
- 🇺🇸
Nemours Children's Hospital, Orlando, Florida, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.